ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy.

Donna Przepiorka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.